CH625218A5 - Process for the preparation of N-acetyl-5-methoxy-tryptamine - Google Patents
Process for the preparation of N-acetyl-5-methoxy-tryptamine Download PDFInfo
- Publication number
- CH625218A5 CH625218A5 CH1649974A CH1649974A CH625218A5 CH 625218 A5 CH625218 A5 CH 625218A5 CH 1649974 A CH1649974 A CH 1649974A CH 1649974 A CH1649974 A CH 1649974A CH 625218 A5 CH625218 A5 CH 625218A5
- Authority
- CH
- Switzerland
- Prior art keywords
- indole
- indigo
- hydroxy
- acetyl
- tryptamine
- Prior art date
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims description 14
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims description 14
- 238000000034 method Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 8
- 229940097275 indigo Drugs 0.000 claims description 8
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 6
- LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-hydroxyindole Chemical compound OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 claims description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 229940097276 5-methoxytryptamine Drugs 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- MWXGHSLSDGMCCC-UHFFFAOYSA-N 2-(1H-indol-5-ylmethoxy)ethanamine Chemical compound NCCOCC=1C=C2C=CNC2=CC1 MWXGHSLSDGMCCC-UHFFFAOYSA-N 0.000 claims description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 2
- 239000012346 acetyl chloride Substances 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 2
- 238000000197 pyrolysis Methods 0.000 claims description 2
- IPCXNCATNBAPKW-UHFFFAOYSA-N zinc;hydrate Chemical compound O.[Zn] IPCXNCATNBAPKW-UHFFFAOYSA-N 0.000 claims 1
- JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229960003987 melatonin Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241001062009 Indigofera Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- SWHZGSSFRJHKDK-UHFFFAOYSA-N 3-(1H-pyrrol-2-ylmethyl)phenol Chemical compound OC1=CC=CC(CC=2NC=CC=2)=C1 SWHZGSSFRJHKDK-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- -1 3- (2-aminoethyl) -5-hydroxy-benzyl-pyrrole Chemical compound 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010054834 Hypergonadism Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT4011573 | 1973-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH625218A5 true CH625218A5 (en) | 1981-09-15 |
Family
ID=11248376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1649974A CH625218A5 (en) | 1973-12-31 | 1974-12-11 | Process for the preparation of N-acetyl-5-methoxy-tryptamine |
Country Status (10)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4506080A (en) * | 1983-07-01 | 1985-03-19 | Nestec S. A. | Preparation of serotonine and derivatives |
| GB8727099D0 (en) * | 1987-11-19 | 1987-12-23 | Cellena Cell Eng A G | Compositions containing melantonin/homologues |
| GR900100024A (el) * | 1989-01-17 | 1991-06-07 | Amr Int | Μέθοδος θεραπείας του προεμμηνορροϊκού συνδρόμου. |
| IT1243193B (it) * | 1990-08-10 | 1994-05-24 | Medea Res Srl | Composizioni farmaceutiche orali a base di melatonina |
-
1974
- 1974-07-19 DE DE2435365A patent/DE2435365A1/de active Pending
- 1974-07-26 AT AT617674A patent/ATA617674A/de not_active Application Discontinuation
- 1974-08-01 AU AU71949/74A patent/AU7194974A/en not_active Expired
- 1974-11-28 FR FR7440379A patent/FR2255897A1/fr not_active Withdrawn
- 1974-12-11 CH CH1649974A patent/CH625218A5/it not_active IP Right Cessation
- 1974-12-27 JP JP49149047A patent/JPS5096565A/ja active Pending
- 1974-12-30 ZA ZA00748264A patent/ZA748264B/xx unknown
- 1974-12-31 NL NL7417046A patent/NL7417046A/xx unknown
- 1974-12-31 GB GB33039/74A patent/GB1493941A/en not_active Expired
- 1974-12-31 BE BE152074A patent/BE824022A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA748264B (en) | 1976-01-28 |
| FR2255897A1 (enrdf_load_stackoverflow) | 1975-07-25 |
| NL7417046A (nl) | 1975-07-02 |
| GB1493941A (en) | 1977-11-30 |
| AU7194974A (en) | 1976-02-05 |
| JPS5096565A (enrdf_load_stackoverflow) | 1975-07-31 |
| DE2435365A1 (de) | 1976-01-29 |
| ATA617674A (de) | 1976-11-15 |
| BE824022A (fr) | 1975-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102939287B (zh) | 雌激素受体调节剂及其用途 | |
| JPS60246375A (ja) | ピリダジノン、その製法並びに該化合物を含有する気管支疾患治療剤 | |
| US4299838A (en) | Tryptophan derivatives having an increased effect on the central nervous system | |
| TW200806637A (en) | Synthesis of triazole compounds that modulate HSP90 activity | |
| JPS6358817B2 (enrdf_load_stackoverflow) | ||
| TW202128668A (zh) | 并環類衍生物、其製備方法及其在醫藥上的應用 | |
| BRPI0609191A2 (pt) | mÉtodos e compostos moduladores de receptor de androgÊnio | |
| MX2007014988A (es) | Complejo de principio activo estable de sales del acido o-acetilsalicilico con aminoacidos y glicina. | |
| JP2023505289A (ja) | Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用 | |
| JP2022519268A (ja) | Ｐａｒｐ阻害剤としてのインドロヘプタアシルオキシム類似体 | |
| DE69330754T2 (de) | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINE ALS NMDA REZEPTOR ANTAGONISTEN | |
| DE4115215A1 (de) | Indolderivate | |
| WO2004091605A1 (ja) | アルキルエーテル誘導体またはその塩を含有する網膜神経疾患の予防・治療剤 | |
| Wyrick et al. | Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogs | |
| JPS62228016A (ja) | 非−白金抗癌薬によりひき起こされる嘔吐の軽減用治療剤 | |
| CH625218A5 (en) | Process for the preparation of N-acetyl-5-methoxy-tryptamine | |
| DE69226299T2 (de) | 6-Heterocyclisch-4-amino-1,2,2a,3,4,5-Hexahydrobenz[CD]indole | |
| JPH08502037A (ja) | ４環性化合物、これらを調整するための方法及び中間体並びに抗腫瘍剤としてのこれらの使用 | |
| JPH023680A (ja) | ５−メトキシトリプタミン及びトリプタミン誘導体の合成方法 | |
| JPH02300184A (ja) | インドール誘導体 | |
| WO1994017058A1 (en) | Imidazole compound | |
| US3467755A (en) | Compositions and methods for producing sedation and tranquilization with substituted 4,5,6,7- tetrahydro-4-oxindoles | |
| JPS5849557B2 (ja) | 新規インド−ルまたはアザインド−ル化合物の製法 | |
| JPS58208275A (ja) | ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤 | |
| JPS60501561A (ja) | アゾ−ビス−サリチル酸およびその塩、該酸および該塩の薬学的処方および使用、並びに該酸の製造 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |